Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2015 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio

Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)...
April 16, 2015 12:26 ET | Source: NOVARTIS FINANCE S.A.

Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg

Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full range of...
March 06, 2015 09:10 ET | Source: NOVARTIS FINANCE S.A.

FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz

Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the...
February 13, 2015 11:30 ET | Source: NOVARTIS FINANCE S.A.

Novartis' heart failure medicine LCZ696 granted FDA priority review

Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] Nearly...
January 27, 2015 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses

Net sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7...
January 25, 2015 16:22 ET | Source: NOVARTIS FINANCE S.A.

Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US

With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible...
November 28, 2014 01:15 ET | Source: NOVARTIS FINANCE S.A.

Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1]

Decision by EU review body could speed access to LCZ696 for HFrEF patients in the EU LCZ696 is the first investigational cardiovascular drug to be granted accelerated assessment, shortening the...
November 21, 2014 01:15 ET | Source: NOVARTIS FINANCE S.A.

Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients

Cosentyx (secukinumab, formerly AIN457) is recommended as first-line systemic therapy for the treatment of moderate-to-severe plaque psoriasis in adult patients in Europe In Phase III studies,...
November 17, 2014 16:45 ET | Source: NOVARTIS FINANCE S.A.

Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2]

New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus...
October 28, 2014 02:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter

Net sales up 4% (+5% cc)[1] in Q3, with operating margin increase across Q3 and 9M Net sales of USD 14.7 billion grew 4% (+5% cc[2]) in Q3 Strong operating income growth in Q3 of 14% (+18% cc)...